PRECLINICAL STUDIES IN ONCOLOGY AND IMMUNO-ONCOLOGY
exploring potential treatments and predicting outcomes with the latest oncology and immuno-oncology in vivo models.
KEEPING THE KAPLAN MEIER CURVES HIGH
Every 30 seconds, a new cancer is diagnosed in the United State; More than 100 types of cancer exist, each one having multiple subtypes. This has led to the development of a plethora of models that accurately replicate both the host and the tumor microenvironment, allowing new treatments to be tailored in accordance with optimal biological dynamics.
The only thing you need to advance your next cancer research breakthrough is the right partner – a partner you can find in PharmaLegacy.
Keep scrolling to check out our oncology and immuno-oncology models: your next step towards a potential cure.
Top Pharmaceutical Companies Trust PharmaLegacy for their Oncology Trials
“The study they delivered on a very reasonable budget was top notch […] The model was executed flawlessly.”
See why a top-20 pharmaceutical company trusts PharmaLegacy for their preclinical immuno-oncology trials.
The capability to succeed:
- Operations and IT structured for maximum protection of clients’ data and IP
- Rigorous adherence to international GLP and QA best practices
- 600+ validated animal models of disease spanning 40+ diseases
- On-site capacity for up to 350 non-human primates, with off-site capacity for up to 30,000 Cynomolgus and Rhesus monkeys